Pfizer Inc.
NYSE•PFE
CEO: Dr. Albert Bourla D.V.M., Ph.D.
Sector: Healthcare
Industry: Drug Manufacturers - General
Listing Date: 1972-06-01
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Contact Information
Market Cap
$151.13B
P/E (TTM)
19.4
36.7
Dividend Yield
6.5%
52W High
$27.94
52W Low
$20.92
52W Range
Rank23Top 9.4%
5.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$17.56B+0.00%
4-Quarter Trend
EPS
-$0.29+0.00%
4-Quarter Trend
FCF
$4.50B+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
2025 Financial Performance Summary Total revenues $62.6B, down 2% operationally; Adjusted EPS $3.22, up 4% versus prior year results.
COVID-19 Revenue Contraction Paxlovid revenue dropped 59% operationally; Comirnaty revenue fell 20% operationally, impacting overall financial results.
R&D Savings Reinvestment Plan $500M R&D savings from cost realignment expected to be reinvested in 2026 pipeline development initiatives.
Risk Factors
Patent Expiry Revenue Erosion Anticipate significant revenue reduction from patent/exclusivity expiries accelerating between 2026 through 2030.
Pricing and Access Pressures Ongoing IRA mandates and MFN initiatives create greater pricing pressure across key U.S. commercial markets.
Competitive Product Launches New branded generics and biosimilars may erode sales of existing products, impacting market exclusivity.
Supply Chain Vulnerabilities Risks persist from manufacturing disruptions, shortages, and potential regulatory actions impacting global product distribution.
Outlook
Strategic Growth Opportunities Focus Capitalizing on pipeline advancement via Metsera, Seagen acquisitions, and new YaoPharma/3SBio in-licensing deals.
Cost Reduction Program Execution Executing $5.7B cost realignment goal and $1.5B manufacturing optimization savings through 2027.
2026 Key Priority Delivery Focus on maximizing transaction value, delivering critical R&D milestones, and scaling AI across the business.
Peer Comparison
Revenue (TTM)
$65.01B
$62.58B
$52.71B
Gross Margin (Latest Quarter)
92.7%
86.8%
81.9%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| MRK | $296.27B | 16.3 | 36.2% | 36.9% |
| AMGN | $203.23B | 26.4 | 96.7% | 60.3% |
| GILD | $183.52B | 21.6 | 41.0% | 41.7% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
8.6%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow
Deep Research
Next earnings:Apr 27, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data